# 3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF

> **NCT02267655** · PHASE1 · COMPLETED · sponsor: **Bellerophon** · enrollment: 8 (actual)

## Conditions studied

- Pulmonary Hypertension
- Chronic Obstructive Pulmonary Disease
- Idiopathic Pulmonary Fibrosis

## Interventions

- **DRUG:** inhaled Nitric Oxide - 30 mcg/kg IBW/hr
- **DRUG:** inhaled Nitric Oxide 5,10,15 mcg/Kg IBW/hr
- **DRUG:** inhaled nitric oxide 75 mcg/kg IBW/hr

## Key facts

- **NCT ID:** NCT02267655
- **Lead sponsor:** Bellerophon
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-05
- **Primary completion:** 2017-06
- **Final completion:** 2017-06-28
- **Target enrollment:** 8 (ACTUAL)
- **Last updated:** 2023-02-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02267655

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02267655, "3 Part Study to Assess Inhaled Nitric Oxide on Functional Pulmonary Imaging in Subj. Pulmonary Hypertension Associated w/ COPD and IPF". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02267655. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*